您当前所在的位置:首页 > 产品中心 > 产品详细信息
7261-97-4 分子结构
点击图片或这里关闭

1-({[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)imidazolidine-2,4-dione

ChemBase编号:1089
分子式:C14H10N4O5
平均质量:314.253
单一同位素质量:314.06511944
SMILES和InChIs

SMILES:
o1c(c2ccc([N+](=O)[O-])cc2)ccc1/C=N/N1CC(=O)NC1=O
Canonical SMILES:
O=C1CN(C(=O)N1)/N=C/c1ccc(o1)c1ccc(cc1)[N+](=O)[O-]
InChI:
InChI=1S/C14H10N4O5/c19-13-8-17(14(20)16-13)15-7-11-5-6-12(23-11)9-1-3-10(4-2-9)18(21)22/h1-7H,8H2,(H,16,19,20)
InChIKey:
OZOMQRBLCMDCEG-UHFFFAOYSA-N

引用这个纪录

CBID:1089 http://www.chembase.cn/molecule-1089.html

Collapse All Expand All

名称和登记号

名称和登记号

名称 登记号
IUPAC标准名
1-({[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)imidazolidine-2,4-dione
IUPAC传统名
dantroleno
sodium, dantrolene
商标名
Dantrium
Dantrium Intravenous
别名
Dantrolene Sodium
Dantroleno [INN-Spanish]
Dantrolenum [INN-Latin]
Dantrolene
1-({[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)imidazolidine-2,4-dione
CAS号
7261-97-4
MDL号
MFCD00867709
PubChem SID
160964552
PubChem CID
2952
6914273
CHEBI ID
4317
ATC码
M03CA01
CHEMBL
1201288
Chemspider ID
2847
DrugBank ID
DB01219
IUPHAR配体索引
4172
KEGG ID
D02347
美国药典/FDA物质标识码
F64QU97QCR
维基百科标题
Dantrolene

数据来源

数据来源

所有数据来源 商品来源 非商品来源
数据来源 数据ID 价格
Enamine
EN300-119181 external link 加入购物车 请登录

理论计算性质

理论计算性质

JChem ALOGPS 2.1
Acid pKa 9.233154  质子受体
质子供体 LogD (pH = 5.5) 1.2564061 
LogD (pH = 7.4) 1.2502273  Log P 1.2564855 
摩尔折射率 78.8745 cm3 极化性 29.878029 Å3
极化表面积 120.73 Å2 可自由旋转的化学键
里宾斯基五规则 true 
Log P 1.65  LOG S -3.59 
溶解度 8.05e-02 g/l 

分子性质

分子性质

理化性质 药理学性质 产品相关信息 生物活性(PubChem)
溶解度
Low (146 mg/L) expand 查看数据来源
疏水性(logP)
1.631 expand 查看数据来源
1.7 expand 查看数据来源
给药途径
Oral, intravenous expand 查看数据来源
生物利用度
70% expand 查看数据来源
排泄
Biliary, renal expand 查看数据来源
代谢
Liver expand 查看数据来源
妊娠期药物分类
C (US) expand 查看数据来源
纯度
95% expand 查看数据来源

详细说明

详细说明

DrugBank DrugBank Wikipedia Wikipedia
DrugBank -  DB01219 external link
Item Information
Drug Groups approved
Description Chemically, dantrolene is a hydantoin derivative, but does not exhibit antiepileptic activity like other hydantoin derivates such as phenytoin.
Indication For use, along with appropriate supportive measures, for the management of the fulminant hypermetabolism of skeletal muscle characteristic of malignant hyperthermia crises in patients of all ages. Also used preoperatively, and sometimes postoperatively, to prevent or attenuate the development of clinical and laboratory signs of malignant hyperthermia in individuals judged to be malignant hyperthermia susceptible.
Pharmacology Dantrolene is classified as a direct-acting skeletal muscle relaxant. It is currently the only specific and effective treatment for malignant hyperthermia. In isolated nerve-muscle preparation, Dantrium has been shown to produce relaxation by affecting the contractile response of the muscle at a site beyond the myoneural junction. In skeletal muscle, Dantrium dissociates excitation-contraction coupling, probably by interfering with the release of Ca2+ from the sarcoplasmic reticulum. In the anesthetic-induced malignant hyperthermia syndrome, evidence points to an intrinsic abnormality of skeletal muscle tissue. In selected humans, it has been postulated that “triggering agents” (e.g.,general anesthetics and depolarizing neuromuscular blocking agents) produce a change within the cell which results in an elevated myoplasmic calcium. This elevated myoplasmic calcium activates acute cellular catabolic processes that cascade to the malignant hyperthermia crisis. It is hypothesized that addition of Dantrium to the “triggered” malignant hyperthermic muscle cell reestablishes a normal level of ionized calcium in the myoplasm.
Toxicity Oral LD50 in rats is 7400 mg/kg. Symptoms which may occur in case of overdose include, but are not limited to, muscular weakness and alterations in the state of consciousness (e.g., lethargy, coma), vomiting, diarrhea, and crystalluria.
Affected Organisms
Humans and other mammals
Biotransformation Hepatic, most likely by hepatic microsomal enzymes. Its major metabolites in body fluids are 5-hydroxydantrolene and an acetylamino metabolite of dantrolene. Another metabolite with an unknown structure appears related to the latter. Dantrium may also undergo hydrolysis and subsequent oxidation forming nitrophenylfuroic acid.
Absorption Bioavailability is 70%.
Half Life The mean biologic half-life after intravenous administration is variable, between 4 to 8 hours under most experimental conditions, while oral is 8.7 hours for a 100mg dose.
Protein Binding Significant, mostly to albumin.
References
Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F: Dantrolene--a review of its pharmacology, therapeutic use and new developments. Anaesthesia. 2004 Apr;59(4):364-73. [Pubmed]
External Links
Wikipedia
RxList
Drugs.com

参考文献

参考文献

供应商提供 Google Scholar IconGoogle Scholar PubMed iconPubMed Google Books IconGoogle Books
  • Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F: Dantrolene--a review of its pharmacology, therapeutic use and new developments. Anaesthesia. 2004 Apr;59(4):364-73. Pubmed
正在搜索,请耐心等待...(如果遇到网页错误或者长时间没有结果,请刷新页面[F5])

专利

专利

PubChem iconPubChem Patent Google Patent Search IconGoogle Patent

互联网资源

互联网资源

百度图标百度 google iconGoogle